Prexton Therapeutics
mGluR4 compounds for Parkinson’s disease
Prexton Therapeutics aims to advance the standard of care for Parkinson’s disease by developing a therapeutic that strategically targets metabotropic glutamate receptor 4. It plans to use its lead compound as an add-on therapy to facilitate lower therapeutic doses of L-dopa in order to decrease adverse effects, while maintaining the expected therapeutic level of the treatment.